Skip to main content
Windlas Biotech Limited logo

Windlas Biotech Limited — Investor Relations & Filings

Ticker · WINDLAS ISIN · INE0H5O01029 LEI · 3358008HGGLMCSC4GP83 BSE.NS Manufacturing
Open in API
Filings indexed 433 across all filing types
Latest filing 2025-05-22 Earnings Release
Country IN India
Listing BSE.NS WINDLAS

About Windlas Biotech Limited

https://www.windlasbiotech.com

Windlas Biotech Limited is a Contract Development and Manufacturing Organization (CDMO) providing integrated services from formulation development to commercial-scale production. The company specializes in manufacturing solid and liquid oral dosage forms, including tablets, capsules, sachets, and liquid orals. Its operations encompass three primary business verticals: CDMO services for domestic and multinational firms, trade generics, and over-the-counter (OTC) brands. Windlas maintains advanced research and development facilities focused on process optimization and complex generic formulations. The product portfolio covers diverse therapeutic areas such as gastrointestinal, cardiovascular, anti-diabetic, and respiratory health. The company emphasizes scalable manufacturing solutions and adherence to global quality standards to support the product lifecycles of its pharmaceutical partners.

Recent filings

Filing Released Lang Actions
Press Release
Earnings Release Classification · 95% confidence The document is a press release dated May 22, 2025, announcing Windlas Biotech Limited's audited financial results for the quarter and fiscal year ended March 31, 2025. It contains detailed financial highlights including revenue, EBITDA, PAT, EPS, and segment performance for Q4 and FY25. The document is not a full annual report but an initial announcement of quarterly and annual financial results. It is not merely a notification or a certification but includes substantive financial data and management commentary on performance and outlook. Therefore, it fits the definition of an Earnings Release (ER), which is the initial announcement of quarterly/periodical financial results with key highlights.
2025-05-22 English
Investor Presentation
Investor Presentation Classification · 95% confidence The document is a detailed presentation titled 'Windlas Biotech Limited Investor Presentation – May 2025' and includes comprehensive financial performance data for the quarter and financial year ended March 31, 2025. It contains extensive financial statements, management messages, revenue and EBITDA figures, segment performance, and shareholder dividend information. The document is about 15,000 characters long, indicating it is a full report rather than a brief announcement. The content is consistent with an investor presentation focusing on financials, strategy, and market position rather than a formal annual report or earnings release. The presence of detailed financial highlights and forward-looking statements further supports this classification. Therefore, the document fits best under the category 'Investor Presentation' (IP).
2025-05-22 English
Outcome of Board Meeting
Regulatory Filings
2025-05-22 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a notification from Windlas Biotech Limited about the scheduling of a conference call to discuss the financial performance for the quarter and financial year ended March 31, 2025. It includes details such as date, time, and call-in numbers, and mentions key participants. There are no actual financial statements or detailed financial analysis included in the text. The document serves as an announcement of an upcoming conference call rather than the transcript or report of the call itself. Therefore, it fits the category of a Call Transcript (CT) only if it contained the full transcript, but since it is only a schedule/announcement, it is best classified as a Regulatory Filing (RNS) as a general regulatory announcement about the conference call. However, given the filing definitions, the closest specific category is Call Transcript (CT) only if the full transcript is present. Since this is only a schedule notice, it is a Regulatory Filing (RNS). Confidence is high due to clear identification of the document as a conference call schedule notice without financial data or transcript.
2025-05-14 English
Board Meeting — Board Meeting Intimation
Regulatory Filings
2025-05-14 English
Board Meeting — Financial Results/Dividend
Regulatory Filings Classification · 95% confidence The document is a notice from Windlas Biotech Limited announcing a scheduled Board Meeting on May 22, 2025. The purpose of the meeting includes consideration and approval of audited financial results for the quarter and year ended March 31, 2025, and recommendation of dividend. The document is a formal announcement to stock exchanges and compliance departments about the upcoming board meeting and related procedural information such as trading window closure. It does not contain the financial results themselves, nor detailed financial data or analysis. The document is short (1948 characters) and serves as a notification rather than a report. Therefore, it fits the category of a Regulatory Filing (RNS) as a general regulatory announcement rather than an Annual Report, Interim Report, or Earnings Release. It is not a Report Publication Announcement since it does not mention the report being published or attached, but rather the meeting to approve such reports.
2025-05-14 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.